Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name (Ascending) Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
71921-0177-06 71921-0177 Abiraterone acetate Abiraterone acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 10, 2023 In Use
63629-9429-01 63629-9429 Abiraterone acetate Abiraterone Acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Aug. 23, 2022 In Use
63629-9430-01 63629-9430 Abiraterone acetate Abiraterone Acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Aug. 23, 2022 In Use
72205-0284-05 72205-0284 Abiraterone acetate Abiraterone 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral May 24, 2024 In Use
72205-0284-92 72205-0284 Abiraterone acetate Abiraterone 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral May 24, 2024 In Use
72205-0285-05 72205-0285 Abiraterone acetate Abiraterone 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral May 24, 2024 In Use
72205-0285-60 72205-0285 Abiraterone acetate Abiraterone 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral May 24, 2024 In Use
82009-0139-12 82009-0139 Abiraterone acetate Abiraterone 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral June 15, 2024 In Use
82009-0140-60 82009-0140 Abiraterone acetate Abiraterone 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral July 16, 2024 In Use
00591-4365-60 00591-4365 Abiraterone acetate Abiraterone acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral July 13, 2023 In Use
72162-2151-06 72162-2151 Abiraterone acetate Abiraterone Acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Dec. 7, 2023 In Use
69539-0318-05 69539-0318 Abiraterone acetate Abiraterone 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 26, 2024 In Use
69539-0318-92 69539-0318 Abiraterone acetate Abiraterone 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 26, 2024 In Use
69539-0319-05 69539-0319 Abiraterone acetate Abiraterone 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 26, 2024 In Use
69539-0319-60 69539-0319 Abiraterone acetate Abiraterone 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 26, 2024 In Use
00310-3512-60 00310-3512 Acalabrutinib CALQUENCE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Aug. 4, 2022 In Use
00310-3512-95 00310-3512 Acalabrutinib CALQUENCE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Aug. 4, 2022 In Use
00310-0512-28 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral April 1, 2018 July 31, 2021 In Use
00310-0512-60 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Oct. 31, 2017 In Use
00310-0512-95 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral April 1, 2020 July 31, 2025 In Use
80739-0812-12 80739-0812 Adagrasib KRAZATI 200.0 mg/1 Immunotherapy RAS Inhibitor KRAS G12C Oral Dec. 12, 2022 In Use
80739-0812-18 80739-0812 Adagrasib KRAZATI 200.0 mg/1 Immunotherapy RAS Inhibitor KRAS G12C Oral Dec. 12, 2022 In Use
00597-0137-30 00597-0137 Afatinib Gilotrif 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug. 9, 2013 In Use
00597-0137-90 00597-0137 Afatinib Gilotrif 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct. 1, 2018 In Use
00597-0138-30 00597-0138 Afatinib Gilotrif 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug. 8, 2013 In Use

Found 10,000 results in 3 milliseconds — Export these results